285.73
+3.01(+1.06%)
Currency In USD
Previous Close | 282.72 |
Open | 286.99 |
Day High | 287.85 |
Day Low | 279.33 |
52-Week High | 377.46 |
52-Week Low | 200.63 |
Volume | 373,858 |
Average Volume | 331,259 |
Market Cap | 6.34B |
PE | -16.01 |
EPS | -17.85 |
Moving Average 50 Days | 296.56 |
Moving Average 200 Days | 295.18 |
Change | 3.01 |
If you invested $1000 in Madrigal Pharmaceuticals, Inc. (MDGL) 10 years ago, it would be worth $3,214.06 as of June 21, 2025 at a share price of $285.73. Whereas If you bought $1000 worth of Madrigal Pharmaceuticals, Inc. (MDGL) shares 5 years ago, it would be worth $2,556.41 as of June 21, 2025 at a share price of $285.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
GlobeNewswire Inc.
Yesterday at 10:30 AM GMT
Positive recommendation based on resmetirom’s favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trialEuropean Commission decision expected in August 2025; if approved, resmetirom will be the first medication for peopl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jun 17, 2025 8:05 PM GMT
CONSHOHOCKEN, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced tha
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
GlobeNewswire Inc.
Jun 02, 2025 12:00 PM GMT
CONSHOHOCKEN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40